{
    "nctId": "NCT02958774",
    "briefTitle": "Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation",
    "officialTitle": "Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 388,
    "primaryOutcomeMeasure": "Lymphedema Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Karnofsky Performance Status 50% - 100%\n* Diagnosis of stage II or III node-positive breast cancer (NOTE: Stages include: T4a-cNany, T3N1, TxN2.) OR T3N0 node-negative breast cancer.\n* For patients with TxN1 disease, one of the following criteria must be met: Grade 3; \u2264 45 years of age at time of screening for this study; extensive Lymphovascular Space Invasion (LVSI); 3 lymph nodes positive; hormone-negative disease; positive lymph nodes after chemotherapy; or extracapsular extension\n* Prior surgery and chemotherapy allowed, no prior radiation to the target area (breast or chest and nodes). NOTE: Radiation should occur 3-12 weeks after last chemotherapy or surgery, whichever comes last.\n* Women of child-bearing potential (WOCP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.\n\nExclusion Criteria:\n\n* Diagnosis of inflammatory breast cancer\n* Previously diagnosed malignancy excluding basal or squamous cell carcinoma of the skin (unless disease-free for 5 years or more)\n* Diagnosis of scleroderma\n* Diagnosis of lupus\n* Diagnosis of active dermatomyositis\n* Diagnosis of metastatic disease\n* Pregnant or nursing",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}